160 related articles for article (PubMed ID: 32500858)
1. Serum Concentrations of Interleukin 6 in the General Adult Population: Possible Implications for Anti-IL-6 Therapy in SARS-Cov-2 Infection and IL-6-Related Diseases.
Alende-Castro V; Alonso-Sampedro M; Gude F; Gonzalez-Quintela A
J Investig Allergol Clin Immunol; 2021 Feb; 31(1):75-78. PubMed ID: 32500858
[No Abstract] [Full Text] [Related]
2. Is IL-6 a key cytokine target for therapy in COVID-19?
Jones SA; Hunter CA
Nat Rev Immunol; 2021 Jun; 21(6):337-339. PubMed ID: 33850327
[TBL] [Abstract][Full Text] [Related]
3. Audio Interview: A New SARS-CoV-2 Vaccine and a New Look at Treatment.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2021 Mar; 384(9):e46. PubMed ID: 33657301
[No Abstract] [Full Text] [Related]
4. Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment.
Wu J; Shen J; Han Y; Qiao Q; Dai W; He B; Pang R; Zhao J; Luo T; Guo Y; Yang Y; Wu Q; Jiang W; Zhang J; Zhang M; Li N; Li W; Xia X
Front Immunol; 2021; 12():598799. PubMed ID: 33746945
[TBL] [Abstract][Full Text] [Related]
5. The shortcomings of tocilizumab in COVID-19.
Tirupathi R; Bharathidasan K; Areti S; Kaur J; Salim S; Al-Tawfiq JA
Infez Med; 2020 Dec; 28(4):465-468. PubMed ID: 33257619
[TBL] [Abstract][Full Text] [Related]
6. Potential effects of itolizumab treatment on plasma interleukin-6 levels in patients with severe COVID-19.
Vityala Y; Tagaev T; Mamatov S; Aidarov Z; Harinath P
Indian J Pharmacol; 2021; 53(3):246-247. PubMed ID: 34169913
[No Abstract] [Full Text] [Related]
7. Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia.
Ulhaq ZS; Soraya GV
Med Clin (Barc); 2020 Dec; 155(12):548-556. PubMed ID: 32950258
[No Abstract] [Full Text] [Related]
8. Rethinking interleukin-6 blockade for treatment of COVID-19.
Scherger S; Henao-Martínez A; Franco-Paredes C; Shapiro L
Med Hypotheses; 2020 Nov; 144():110053. PubMed ID: 32758889
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab, blood cells, and mild COVID-19: delayed vascular protection by interleukin blockade?
Buryachkovskaya L; Lomakin N; Melkumyants A; Docenko J; Serebruany V
Eur Heart J Cardiovasc Pharmacother; 2021 Sep; 7(5):e81-e82. PubMed ID: 34185077
[No Abstract] [Full Text] [Related]
10. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab for hospitalized patients with COVID-19.
Afra K; Chen LYC; Sweet D
CMAJ; 2021 Apr; 193(15):E521. PubMed ID: 33692091
[No Abstract] [Full Text] [Related]
12. Rapid radiological improvement of COVID-19 pneumonia after treatment with tocilizumab.
Comel AC; Mosaner W; Bragantini D; Lanzafame M
Infection; 2021 Feb; 49(1):195-196. PubMed ID: 32557206
[No Abstract] [Full Text] [Related]
13. Interleukin-6: obstacles to targeting a complex cytokine in critical illness.
McElvaney OJ; Curley GF; Rose-John S; McElvaney NG
Lancet Respir Med; 2021 Jun; 9(6):643-654. PubMed ID: 33872590
[TBL] [Abstract][Full Text] [Related]
14. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?
Zhang Y; Zhong Y; Pan L; Dong J
Drug Discov Ther; 2020; 14(2):100-102. PubMed ID: 32378647
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
[TBL] [Abstract][Full Text] [Related]
16. The Importance of the Timing of Tocilizumab Administration in Moderate to Severely Ill COVID-19: Single Centered Experience Case series.
Tenda ED; Andrian S; Albert S; Asaf MM; Pitoyo CW; Setiati S; Subekti I
Acta Med Indones; 2021 Jul; 53(3):319-325. PubMed ID: 34611072
[TBL] [Abstract][Full Text] [Related]
17. The association of interleukin-6 value, interleukin inhibitors, and outcomes of patients with COVID-19 in New York City.
Maeda T; Obata R; Rizk DO D; Kuno T
J Med Virol; 2021 Jan; 93(1):463-471. PubMed ID: 32720702
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab treatment in COVID-19: A single center experience.
Luo P; Liu Y; Qiu L; Liu X; Liu D; Li J
J Med Virol; 2020 Jul; 92(7):814-818. PubMed ID: 32253759
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study.
Chilimuri S; Sun H; Alemam A; Kang KS; Lao P; Mantri N; Schiller L; Sharabun M; Shehi E; Tejada J; Yugay A; Nayudu SK
J Clin Pharm Ther; 2021 Apr; 46(2):440-446. PubMed ID: 33098139
[TBL] [Abstract][Full Text] [Related]
20. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study.
Fernández-Ruiz M; López-Medrano F; Pérez-Jacoiste Asín MA; Maestro de la Calle G; Bueno H; Caro-Teller JM; Catalán M; de la Calle C; García-García R; Gómez C; Laguna-Goya R; Lizasoáin M; Martínez-López J; Origüen J; Pablos JL; Ripoll M; San Juan R; Trujillo H; Lumbreras C; Aguado JM
J Med Virol; 2021 Feb; 93(2):831-842. PubMed ID: 32672860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
